TGA issues SSSI for abatacept

Pharmacists authorised to substitute Orencia 125mg/mL products to deal with shortages  The Therapeutic Goods Administration (TGA) has issued a Serious Scarcity Substitution Instrument (SSSI) in response to shortages of both the Orencia (abatacept) 125mg/mL ClickJect autoinjector for subcutaneous injection and prefilled syringe products.  Bristol-Myers Squibb Australia (BMS) advised the TGA that the two products were

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Demise of dollar discount ‘goes against the grain’
Next No ‘golden ticket’ for reducing risky meds harm